{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:51:38Z","timestamp":1782903098381,"version":"3.54.5"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006485","name":"National Institute for Genetic Engineering and Biotechnology","doi-asserted-by":"publisher","award":["801"],"award-info":[{"award-number":["801"]}],"id":[{"id":"10.13039\/501100006485","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ijbiomac.2025.141916","type":"journal-article","created":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T12:12:12Z","timestamp":1741522332000},"page":"141916","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"P2","title":["MiRGD peptideticle targeted delivery of hinge-truncated soluble VEGF receptor 1 fusion protein to the retinal pigment epithelium cell line and newborn mice retina"],"prefix":"10.1016","volume":"307","author":[{"given":"Somayeh","family":"Piroozmand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra-Soheila","family":"Soheili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Latifi-Navid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahram","family":"Samiei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mozhgan","family":"Rezaei-Kanavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Barzegar","family":"Behrooz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saman","family":"Hosseinkhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijbiomac.2025.141916_bb0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/gt.2008.115","article-title":"Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization","volume":"16","author":"Pechan","year":"2009","journal-title":"Gene Ther."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.141916_bb0010","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1158\/1535-7163.MCT-10-0813","article-title":"sFLT01: a novel fusion protein with antiangiogenic activity","volume":"10","author":"Bagley","year":"2011","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.141916_bb0015","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eurger.2014.09.007","article-title":"Age related macular degeneration\u2013challenge for future: pathogenesis and new perspectives for the treatment","volume":"6","author":"Michalska-Ma\u0142ecka","year":"2015","journal-title":"Eur. Geriat. Med."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.141916_bb0020","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.tjo.2013.09.002","article-title":"Vascular endothelial growth factor and its inhibitor in age-related macular degeneration","volume":"3","author":"Wang","year":"2013","journal-title":"Taiwan J. Ophthalmol."},{"key":"10.1016\/j.ijbiomac.2025.141916_bb0025","series-title":"XII Part, Investigations of Human Retinal Disease","article-title":"Webvision-the organization of the retina and visual system","author":"Kolb","year":"1995"},{"key":"10.1016\/j.ijbiomac.2025.141916_bb0030","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000431128","volume":"55","author":"Gupta","year":"2016","journal-title":"Retinal anatomy and pathology. Retin. Pharmacotherap."},{"key":"10.1016\/j.ijbiomac.2025.141916_bb0035","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-1-4419-9148-5_3","article-title":"Molecular mechanisms of VEGF-induced angiogenesis","author":"Donnini","year":"2004","journal-title":"VEGF and Cancer"},{"key":"10.1016\/j.ijbiomac.2025.141916_bb0040","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.biopha.2018.12.022","article-title":"Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases","volume":"110","author":"Fallah","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.141916_bb0045","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/s41580-023-00631-w","article-title":"Biology and therapeutic targeting of vascular endothelial growth factor a","volume":"24","author":"P\u00e9rez-Guti\u00e9rrez","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.141916_bb0050","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s41573-023-00671-z","article-title":"Targeting angiogenesis in oncology, ophthalmology and beyond","volume":"22","author":"Cao","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.141916_bb0055","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ijbiomac.2025.141916_bb0060","series-title":"And F","author":"Feige","year":"2014"},{"key":"10.1016\/j.ijbiomac.2025.141916_bb0065","first-page":"271","article-title":"Anti-angiogenic therapy for retinal disease","author":"Paulus","year":"2017","journal-title":"Pharmacol. Therapy Ocular Dis."},{"key":"10.1016\/j.ijbiomac.2025.141916_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000353311","article-title":"History of research on angiogenesis","volume":"99","author":"Ribatti","year":"2014","journal-title":"Angiogenesis, Lymphangiogenesis and Clinical Implications"},{"key":"10.1016\/j.ijbiomac.2025.141916_bb0075","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000320006","article-title":"Mechanisms of ocular angiogenesis and its molecular mediators","volume":"46","author":"Siemerink","year":"2010","journal-title":"Anti-VEGF"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.141916_bb0080","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s00018-020-03664-y","article-title":"Endothelial sprouting, proliferation, or senescence: tipping the balance from physiology to pathology","volume":"78","author":"M\u00fchleder","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.141916_bb0085","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1517\/17425247.2014.927864","article-title":"Intravitreal drug delivery in retinal disease: are we out of our depth?","volume":"11","author":"Thakur","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.141916_bb0090","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/pharmaceutics13010108","article-title":"Ocular drug delivery to the retina: current innovations and future perspectives","volume":"13","author":"Kim","year":"2021","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.141916_bb0095","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3390\/pharmaceutics15010205","article-title":"Ocular delivery of therapeutic proteins: a review","volume":"15","author":"Shastri","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2025.141916_bb0100","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.addr.2018.01.008","article-title":"Ocular delivery of proteins and peptides: challenges and novel formulation approaches","volume":"126","author":"Mandal","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.141916_bb0105","first-page":"525","article-title":"Pharmacologic treatment of wet type age-related macular degeneration; current and evolving therapies","volume":"20","author":"Najafabadi","year":"2017","journal-title":"Arch. Iran. Med."},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.141916_bb0110","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1111\/bph.15459","article-title":"Emerging therapies and their delivery for treating age-related macular degeneration","volume":"179","author":"Thomas","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2025.141916_bb0115","doi-asserted-by":"crossref","first-page":"1307860","DOI":"10.3389\/fphar.2023.1307860","article-title":"Recent advances of anti-angiogenic inhibitors targeting VEGF\/VEGFR axis","volume":"14","author":"Wang","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.141916_bb0120","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/mt.2010.230","article-title":"Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule","volume":"19","author":"Lukason","year":"2011","journal-title":"Mol. Ther."},{"issue":"10089","key":"10.1016\/j.ijbiomac.2025.141916_bb0125","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(17)30979-0","article-title":"Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial","volume":"390","author":"Heier","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.141916_bb0130","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/mt.2010.258","article-title":"Preclinical safety evaluation of AAV2-sFLT01\u2014a gene therapy for age-related macular degeneration","volume":"19","author":"MacLachlan","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ijbiomac.2025.141916_bb0135","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2147\/JEP.S259298","article-title":"Current and future anti-VEGF agents for neovascular age-related macular degeneration","author":"Kaiser","year":"2021","journal-title":"J. Exp. Pharmacol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.141916_bb0140","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41434-022-00362-1","article-title":"Design, construction and in vivo functional assessment of a hinge truncated sFLT01","volume":"30","author":"Zakeri","year":"2023","journal-title":"Gene Ther."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.141916_bb0145","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4103\/2230-973X.96920","article-title":"Drug delivery systems: an updated review","volume":"2","author":"Tiwari","year":"2012","journal-title":"Int. J. Pharmaceut. Invest."},{"key":"10.1016\/j.ijbiomac.2025.141916_bb0150","series-title":"Drug delivery for the retina and posterior segment disease","first-page":"107","article-title":"Nano\/Microparticles for Retina and Posterior Diseases","author":"Patel","year":"2018"},{"key":"10.1016\/j.ijbiomac.2025.141916_bb0155","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jconrel.2014.03.054","article-title":"Controlled drug delivery systems: past forward and future back","volume":"190","author":"Park","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2025.141916_bb0160","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jconrel.2015.09.065","article-title":"Delivery strategies for treatment of age-related ocular diseases: from a biological understanding to biomaterial solutions","volume":"219","author":"Delplace","year":"2015","journal-title":"J. Control. Release"},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.141916_bb0165","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s00210-022-02287-3","article-title":"Nanomedicine and drug delivery to the retina: current status and implications for gene therapy","volume":"395","author":"Tawfik","year":"2022","journal-title":"Naunyn Schmiedeberg\u2019s Arch. Pharmacol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.141916_bb0170","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ijpharm.2012.01.062","article-title":"Design, engineering and preparation of a multi-domain fusion vector for gene delivery","volume":"427","author":"Sadeghian","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijbiomac.2025.141916_bb0175","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejpb.2016.06.017","article-title":"Development of novel recombinant biomimetic chimeric MPG-based peptide as nanocarriers for gene delivery: imitation of a real cargo","volume":"107","author":"Majidi","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"5\u20136","key":"10.1016\/j.ijbiomac.2025.141916_bb0180","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.drudis.2008.09.012","article-title":"Gene delivery to the retina: focus on non-viral approaches","volume":"14","author":"Naik","year":"2009","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ijbiomac.2025.141916_bb0185","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.cobme.2018.10.002","article-title":"Gene delivery by peptide-assisted transport","volume":"7","author":"Thapa","year":"2018","journal-title":"Curr. Opin. Biomed. Eng."},{"key":"10.1016\/j.ijbiomac.2025.141916_bb0190","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.2147\/OPTH.S364200","article-title":"Ocular gene therapy: a literature review with special focus on immune and inflammatory responses","author":"Ghoraba","year":"2022","journal-title":"Clin. Ophthalmol."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.141916_bb0195","first-page":"1038","article-title":"Nanotechnology in retinal drug delivery","volume":"11","author":"Jiang","year":"2018","journal-title":"Int. J. Ophthalmol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.141916_bb0200","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.nano.2017.02.007","article-title":"Nano-ophthalmology: applications and considerations","volume":"13","author":"Kamaleddin","year":"2017","journal-title":"Nanomedicine"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.141916_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40123-020-00257-7","article-title":"Therapies based on nanoparticles for eye drug delivery","volume":"9","author":"Meza-Rios","year":"2020","journal-title":"Ophthalmol Therapy"},{"key":"10.1016\/j.ijbiomac.2025.141916_bb0210","first-page":"9285854","article-title":"Protein based nanostructures for drug delivery","volume":"2018","author":"Verma","year":"2018","journal-title":"J. Pharm. (Cairo)"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.141916_bb0215","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3390\/molecules24020351","article-title":"Peptide-based drug-delivery systems in biotechnological applications: recent advances and perspectives","volume":"24","author":"Tesauro","year":"2019","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.141916_bb0220","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jconrel.2009.03.005","article-title":"A designer biomimetic vector with a chimeric architecture for targeted gene transfer","volume":"137","author":"Wang","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2025.141916_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.apcsb.2014.11.001","article-title":"Protein\u2013and peptide\u2013drug conjugates: an emerging drug delivery technology","volume":"98","author":"Vhora","year":"2015","journal-title":"Adv. Protein Chem. Struct. Biol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.141916_bb0230","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3390\/molecules23020295","article-title":"Cell penetrating peptides as molecular carriers for anti-cancer agents","volume":"23","author":"Borrelli","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ijbiomac.2025.141916_bb0235","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.peptides.2014.04.015","article-title":"Cell penetrating peptides: efficient vectors for delivery of nanoparticles, nanocarriers, therapeutic and diagnostic molecules","volume":"57","author":"Farkhani","year":"2014","journal-title":"Peptides"},{"issue":"98","key":"10.1016\/j.ijbiomac.2025.141916_bb0240","doi-asserted-by":"crossref","first-page":"37252","DOI":"10.18632\/oncotarget.26442","article-title":"Cell penetrating peptides in preclinical and clinical cancer diagnosis and therapy","volume":"9","author":"Tripathi","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijbiomac.2025.141916_bb0245","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jconrel.2018.06.023","article-title":"Cell penetrating peptides in ocular drug delivery: state of the art","volume":"284","author":"Pescina","year":"2018","journal-title":"J. Control. Release"},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.141916_bb0250","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.3390\/cells12071071","article-title":"Ocular delivery of therapeutic agents by cell-penetrating peptides","volume":"12","author":"Nh\u00e0n","year":"2023","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.141916_bb0255","doi-asserted-by":"crossref","first-page":"41507","DOI":"10.1038\/srep41507","article-title":"Nano-biomimetic carriers are implicated in mechanistic evaluation of intracellular gene delivery","volume":"7","author":"Alipour","year":"2017","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.141916_bb0260","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1002\/ijc.31577","article-title":"In vivo tumor gene delivery using novel peptideticles: pH-responsive and ligand targeted core\u2013shell nanoassembly","volume":"143","author":"Alipour","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ijbiomac.2025.141916_bb0265","article-title":"Design and preparation of a theranostic peptideticle for targeted cancer therapy: peptide-based codelivery of doxorubicin\/curcumin and graphene quantum dots","volume":"42","author":"Ghafary","year":"2022","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ijbiomac.2025.141916_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115299","article-title":"DNAi-peptide nanohybrid smart particles target BCL-2 oncogene and induce apoptosis in breast cancer cells","volume":"166","author":"Alipour","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ijbiomac.2025.141916_bb0275","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/978-3-540-46826-4_8","article-title":"Adhesive events in retinal development and function: the role of integrin receptors","author":"Clegg","year":"2000","journal-title":"Verteb. Eye Develop."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.141916_bb0280","first-page":"696","article-title":"The integrin superfamily and the eye","volume":"37","author":"Elner","year":"1996","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.141916_bb0285","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.yexcr.2016.08.015","article-title":"Characterization of a spontaneously generated murine retinal pigmented epithelium cell line; a model for in vitro experiments","volume":"347","author":"Pirmardan","year":"2016","journal-title":"Exp. Cell Res."},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.141916_bb0290","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00109-004-0558-8","article-title":"Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection","volume":"82","author":"Dass","year":"2004","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.ijbiomac.2025.141916_bb0295","doi-asserted-by":"crossref","first-page":"15","DOI":"10.12659\/MSMBR.893327","article-title":"Dual AO\/EB staining to detect apoptosis in osteosarcoma cells compared with flow cytometry","volume":"21","author":"Liu","year":"2015","journal-title":"Med. Sci. Monit. Basic Res."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.141916_bb0300","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1167\/iovs.16-20072","article-title":"Topical delivery of anti-VEGF drugs to the ocular posterior segment using cell-penetrating peptides","volume":"58","author":"De Cogan","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.141916_bb0305","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/sj.mt.6300324","article-title":"Cell-penetrating peptide for enhanced delivery of nucleic acids and drugs to ocular tissues including retina and cornea","volume":"16","author":"Johnson","year":"2008","journal-title":"Mol. Ther."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.141916_bb0310","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.visres.2009.08.028","article-title":"Cell penetrating peptide POD mediates delivery of recombinant proteins to retina, cornea and skin","volume":"50","author":"Johnson","year":"2010","journal-title":"Vis. Res."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.141916_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e26616","article-title":"Light-responsive polymeric nanoparticles for retinal drug delivery: design cues, challenges and future perspectives","volume":"10","author":"Guidi","year":"2024","journal-title":"Heliyon"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.141916_bb0320","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2217\/nnm-2016-0379","article-title":"Drug delivery to the eye: what benefits do nanocarriers offer?","volume":"12","author":"Joseph","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ijbiomac.2025.141916_bb0325","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jconrel.2017.01.012","article-title":"Polymeric micelles for ocular drug delivery: from structural frameworks to recent preclinical studies","volume":"248","author":"Mandal","year":"2017","journal-title":"J. Control. Release"},{"issue":"15","key":"10.1016\/j.ijbiomac.2025.141916_bb0330","first-page":"2003699","article-title":"Ocular nanomedicine. Advanced","volume":"9","author":"Tang","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.ijbiomac.2025.141916_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114770","article-title":"Polymer-and lipid-based nanocarriers for ocular drug delivery: current status and future perspectives","volume":"196","author":"Han","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijbiomac.2025.141916_bb0340","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jconrel.2018.06.031","article-title":"Polymer-based carriers for ophthalmic drug delivery","volume":"285","author":"Imperiale","year":"2018","journal-title":"J. Control. Release"},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.141916_bb0345","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.drudis.2019.02.001","article-title":"Design principles of ocular drug delivery systems: importance of drug payload, release rate, and material properties","volume":"24","author":"Subrizi","year":"2019","journal-title":"Drug Discov. Today"},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.141916_bb0350","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/nrm883","article-title":"Signal transduction and endocytosis: close encounters of many kinds","volume":"3","author":"Sorkin","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1\u20132","key":"10.1016\/j.ijbiomac.2025.141916_bb0355","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ijpharm.2016.11.008","article-title":"Development of a targeted anti-HER2 scFv chimeric peptide for gene delivery into HER2-positive breast cancer cells","volume":"515","author":"Cheraghi","year":"2016","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.141916_bb0360","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/gt.2008.185","article-title":"Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV","volume":"16","author":"Singh","year":"2009","journal-title":"Gene Ther."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.141916_bb0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cne.903600102","article-title":"Vitronectin receptor expression and distribution at the photoreceptor-retinal pigment epithelial interface","volume":"360","author":"Anderson","year":"1995","journal-title":"J. Comp. Neurol."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.141916_bb0370","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/jcmm.12070","article-title":"Directional protein secretion by the retinal pigment epithelium: roles in retinal health and the development of age-related macular degeneration","volume":"17","author":"Kay","year":"2013","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.ijbiomac.2025.141916_bb0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12860-021-00367-5","article-title":"sFLT01 modulates invasion and metastasis in prostate cancer DU145 cells by inhibition of VEGF\/GRP78\/MMP2&9 axis","volume":"22","author":"Taghizadeh","year":"2021","journal-title":"BMC Mol. Cell Biol."},{"key":"10.1016\/j.ijbiomac.2025.141916_bb0380","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","article-title":"Tumor angiogenesis: causes, consequences, challenges and opportunities","volume":"77","author":"Lugano","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"issue":"15","key":"10.1016\/j.ijbiomac.2025.141916_bb0385","first-page":"4233","article-title":"Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis","volume":"54","author":"Takahashi","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.141916_bb0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7819-3-68","article-title":"Expression of placenta growth factor (PlGF) in non-small cell lung cancer (NSCLC) and the clinical and prognostic significance","volume":"3","author":"Zhang","year":"2005","journal-title":"World J. Surg. Oncol."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.141916_bb0395","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1167\/iovs.10-5176","article-title":"The mouse retina as an angiogenesis model","volume":"51","author":"Stahl","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.141916_bb0400","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017462","article-title":"Placental growth factor contributes to micro-vascular abnormalization and blood-retinal barrier breakdown in diabetic retinopathy","volume":"6","author":"Kowalczuk","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.141916_bb0405","first-page":"7697031","article-title":"Alginate: current use and future perspectives in pharmaceutical and biomedical applications","volume":"2016","author":"Szekalska","year":"2016","journal-title":"Int. J. Polym. Sci."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.141916_bb0410","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1021\/bc8003167","article-title":"Click chemistry functionalized polymeric nanoparticles target corneal epithelial cells through RGD-cell surface receptors","volume":"20","author":"Lu","year":"2009","journal-title":"Bioconjug. Chem."},{"issue":"17","key":"10.1016\/j.ijbiomac.2025.141916_bb0415","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.3390\/polym14173580","article-title":"Current advances in nano-based and polymeric stimuli-responsive drug delivery targeting the ocular microenvironment: a review and envisaged future perspectives","volume":"14","author":"Dludla","year":"2022","journal-title":"Polymers"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.141916_bb0420","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/s12276-023-01016-x","article-title":"Peptides as multifunctional players in cancer therapy","volume":"55","author":"Vadevoo","year":"2023","journal-title":"Exp. Mol. Med."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.141916_bb0425","first-page":"9367845","article-title":"iRGD: a promising peptide for cancer imaging and a potential therapeutic agent for various cancers","volume":"2019","author":"Zuo","year":"2019","journal-title":"J. Oncol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.141916_bb0430","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3390\/pharmaceutics16020240","article-title":"Peptide-mediated Nanocarriers for targeted drug delivery: developments and strategies","volume":"16","author":"Wang","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2025.141916_bb0435","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2147\/IJN.S126865","article-title":"Topical ocular delivery to laser-induced choroidal neovascularization by dual internalizing RGD and TAT peptide-modified nanoparticles","author":"Chu","year":"2017","journal-title":"Int. J. Nanomedicine"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.141916_bb0440","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3390\/pharmaceutics14020243","article-title":"MicroRNA-539-5p-loaded PLGA nanoparticles grafted with iRGD as a targeting treatment for choroidal neovascularization","volume":"14","author":"Alanazi","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2025.141916_bb0445","first-page":"279","article-title":"Preparation of arginine\u2013glycine\u2013aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization","author":"Chang","year":"2017","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ijbiomac.2025.141916_bb0450","series-title":"Nanoparticles Targeting Retinal and Choroidal Capillaries In Vivo","first-page":"391","author":"Haunberger","year":"2019"}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025024675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025024675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:42:09Z","timestamp":1782902529000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813025024675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":90,"alternative-id":["S0141813025024675"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.141916","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MiRGD peptideticle targeted delivery of hinge-truncated soluble VEGF receptor 1 fusion protein to the retinal pigment epithelium cell line and newborn mice retina","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.141916","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"141916"}}